Top in endocrinology: Type 1 diabetes progression in children; tubeless insulin patch pump
Click Here to Manage Email Alerts
Higher consumption of rye, oats and fruits increased the risk for progression to type 1 diabetes among children at high genetic risk for the disease, study results showed.
“The foods that we found to be associated with the type 1 disease process are nutritionally very important in the diet of young children,” Suvi M. Virtanen, MD,PhD, MSc, research professor at the Finnish Institute for Health and Welfare, told Healio. “We should urgently find out what is behind the associations and what explains them to be able to prevent the disease.”
It was the top story in endocrinology last week.
In another top story, the FDA granted 510(k) clearance for Embecta’s tubeless insulin patch pump system for patients with type 1 or type 2 diabetes.
Read these and more top stories in endocrinology below:
Eating more oats, fruits in early childhood may raise risk for type 1 diabetes
Young children at high genetic risk for type 1 diabetes may be more likely to progress to the disease based on their dietary intake, according to a presenter at the European Association for the Study of Diabetes annual meeting. Read more.
Tubeless insulin patch pump receives FDA clearance for type 1 and type 2 diabetes
The FDA has granted 510(k) clearance for an insulin patch pump for adults with type 1 or type 2 diabetes, Embecta Corp. announced. Read more.
Liraglutide 3 mg reduces BMI for children with obesity aged 6 to 11 years
Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting. Read more.
QWINT: Once-weekly insulin tied to similar HbA1c reduction as insulin degludec
Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog. Read more.
Once-weekly batoclimab lowers immunoglobulin for adults with uncontrolled Graves’ disease
Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant. Read more.